;

Bicycle Therapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer’s 2019 Annual Meeting

31/10/2019

Bicycle Therapeutics, a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) technology, today announced that new preclinical data from BT7480, a potent tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), will be presented during speaker and poster sessions at the Society for Immunotherapy of Cancer’s (SITC) 2019 Annual Meeting on November 6-10, 2019 in National Harbor, MD.

“Our novel and proprietary Bicycle tumor-targeted immune cell agonists, or TICAs, are fully synthetic approaches engineered to overcome the limitations of other immunomodulatory mechanisms,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “The constrained nature of Bicycles confers high affinity and selectivity and enables us to easily link tumor targeting Bicycles to Bicycles that agonize CD137, providing tumor-specific effects. In preclinical experiments with BT7480, we have shown these characteristics promote rapid tumor penetration and powerful anti-tumor activity. We believe that these features, along with the modular nature of the Bicycle platform, could position Bicycles at the cutting edge of next generation immuno-oncology treatments and we look forward to progressing BT7480 into IND-enabling studies.”

BT7480 has shown very potent and tumor antigen dependent CD137 agonism in ex vivo experiments using patient-derived lung tumor samples that have intact immune microenvironments. In a Nectin-4 overexpressing syngeneic tumor model, 92% (n=24) of animals dosed with BT7480 experienced complete tumor regressions. Five of the complete responder animals were subsequently re-challenged with the same tumor cell implantation and no tumor growth was observed, implying development of immunogenic memory. In addition to these data on BT7480, the Company will also present preclinical data at SITC on other emergent Bicycle TICA strategies.

 

Details on Bicycle’s SITC presentations are as follows:
Session Title: Session 2: Novel Platforms and Innovation
Location: Cherry Blossom Ballroom
Oral Presentation Title: A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism
Presenter: Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics
Date & Time: Wednesday, November 6, 2019 4:35 p.m. – 4:45 p.m. ET

Session Title: Novel Single-Agent Immunotherapies
Location: Prince George's Exhibition Halls AB
Poster Presentation Title: A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism
Abstract #: P782
Date & Time: Saturday, November 9, 2019, 7:00 a.m. – 8:30 p.m. ET

Session Title: Novel Single-Agent Immunotherapies
Location: Prince George's Exhibition Halls AB
Poster Presentation Title: A novel fully synthetic dual targeted EphA2/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism
Abstract #: P794
Date & Time: Saturday, November 9, 2019, 7:00 a.m. – 8:30 p.m. ET

 

About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

 

Article sourced from: https://www.businesswire.com/news/home/20191105005675/en/
Published on: 05/11/2019

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;